-
Mashup Score: 1The 2025 Guideline Update Endorses Ticagrelor Monotherapy After ≥1 Month of DAPT Post-PCI in Patients With ACS: Is the Evidence Conclusive? - 16 day(s) ago
Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA ∗Address for correspondence: Dr Sanjay Kaul, Department of Cardiology, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 485W, Los Angeles, California 90048, USA. E-mail: E-mail Address: [email protected] Department of Medicine and Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada Identifying strategies to mitigate bleeding risk with dual antiplatelet therapy (DAPT)
Source: www.jacc.orgCategories: General Medicine NewsTweet
-
Mashup Score: 20Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery - 23 day(s) ago
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers…
Source: abbott.mediaroom.comCategories: General Medicine NewsTweet-
https://t.co/pYDp3SKIdb How many devices are approved by the FDA based on small (n<110), open-label, single-arm, non-randomized trial?
-
-
Mashup Score: 20Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery - 23 day(s) ago
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers…
Source: abbott.mediaroom.comCategories: General Medicine NewsTweet-
https://t.co/pYDp3SKIdb How many devices are approved by the FDA based on small (n<110), open-label, single-arm, non-randomized trial?
-
-
Mashup Score: 9Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes | NEJM - 24 day(s) ago
Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. We enrolled 4162 patients who had been …
Source: www.nejm.orgCategories: General Medicine NewsTweet-
In this sample of 226 votes, majority, by 2:1, preferred formal inference of B is ‘not noninferior’, although both are correct. Data are actually from PROVE-IT trial that aimed to establish NI of 40mg pravastatin (B) relative to 80mg atorvastatin (A). https://t.co/Y2SAhlVesd https://t.co/vuAWw4yFse
-
-
Mashup Score: 8Unblinded trials of transcatheter interventions with subjective endpoints: what are the implications? - 1 month(s) ago
FDA approval of transcatheter devices for severe tricuspid regurgitation sparks debate on validity of unblinded trials with bias-prone outcomes.
Source: eurointervention.pcronline.comCategories: General Medicine NewsTweet-
"TRISCEND II investigators assert that magnitude & durability of health status benefit (HSB), emergence of HSB over first 6m, & relationship between TR severity & HSB provide circumstantial evidence of true biological effect." Does it r/o placebo effect? https://t.co/n4BgGdwHyi
-
-
Mashup Score: 7Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Is Enthusiasm Exceeding the Evidence? - 2 month(s) ago
∗Address for correspondence: Dr Sanjay Kaul, Department of Cardiology, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 485W, Los Angeles, California 90048, USA. E-mail: E-mail Address: [email protected] Copyright © 2025, American College of Cardiology Foundation. Published by Elsevier Received February 24, 2025 Accepted March 3, 2025 Published online April 7,
Source: www.jacc.orgCategories: General Medicine NewsTweet-
For the 8 out of 38 who voted Yes, here is something to ponder. 👇 https://t.co/YL7Y3TaArh Feel free to recalibrate your views if you must! https://t.co/V9H1QejKa2
-
-
Mashup Score: 7Home Page - 2 month(s) ago
The DOI Foundation is a not-for-profit organization. We govern the Digital Object Identifier (DOI) system on behalf of the agencies who manage DOI registries and provide services to their respective communities. We are the registration authority for the ISO standard (ISO 26324) for the DOI system and we are governed by our Registration Agencies. We are an international community of communities bound by a common interest in persistent infrastructure. So far, we have welcomed agencies that manage communities
Source: www.doi.orgCategories: General Medicine NewsTweet-
Are claims that time has come for “…routine & preferred strategy for asymptomatic AS patients to shift from watchful waiting to prompt AVR...” justified? https://t.co/MDjMiFYDfT 10.1001/jamacardio.2024.5648
-
-
Mashup Score: 11
Data from randomized trials evaluating the effectiveness of tuberculosis (TB) preventive treatment for contacts of multidrug-resistant (MDR)-TB are lacking. Two recently published randomized trials…
Source: evidence.nejm.orgCategories: General Medicine News, CardiologistsTweet-
https://t.co/JFKEsjGkub VQUIN (Vietnam) N=2041, median age 40y Placebo event rate: 1.1% observed vs 3% expected 80% power to detect 70% RRR PEP (incident TB): IRR 0.55, 0.19-1.62; since 70% RRR is contained within 95% CI, this is an inconclusive result due to inadequate power
-
-
Mashup Score: 78
This meta-analysis evaluates the ratio of heart failure (HF) to all-cause hospitalizations in randomized clinical trials, whether differences in all-cause hospitalization can be inferred from reported treatment effects on HF hospitalization, and how frequently these are reported.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet-
Should Heart Failure Trials routinely report on all-cause hospitalizations? Should clinicians, guidelines & payers favor interventions that favorably impact cause-specific & all-cause outcomes? https://t.co/R2AOvXZNPB https://t.co/CemQrsNKKm @AndrewFoy82 @drjohnm
-
-
Mashup Score: 73
This meta-analysis evaluates the ratio of heart failure (HF) to all-cause hospitalizations in randomized clinical trials, whether differences in all-cause hospitalization can be inferred from reported treatment effects on HF hospitalization, and how frequently these are reported.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet-
Should Heart Failure Trials routinely report on all-cause hospitalizations? Should clinicians, guidelines & payers favor interventions that favorably impact cause-specific & all-cause outcomes? https://t.co/R2AOvXZNPB https://t.co/CemQrsNKKm @AndrewFoy82 @drjohnm
-
Close Call with 56% voting for European guidelines being more faithful to the evidence. Our perspective is more aligned with the European guideline which give a weak recommendation for abbreviated DAPT to mitigate bleeding. 👇🏻 https://t.co/KzeiWQbGzZ @JACCJournals @brophyj https://t.co/faKPOendkD